Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific (“APAC”) (the “Nizoral Rights”) from Janssen Pharmaceutica NV (a member of the Johnson & Johnson group of companies) (the “Vendor”) for a total consideration of £60.0 million (the “Acquisition”).

The Acquisition, which will boost Alliance’s successful and rapidly growing APAC distributor business, is expected to generate material earnings enhancement in the first full year of ownership.

The Acquisition will be funded by an underwritten equity placing of new ordinary shares in the capital of the Company to raise gross proceeds of £34.0 million (c. £32.1 million net of transaction expenses) (the “Placing”) at an indicative placing price of 91 pence per Placing Share, to be confirmed pursuant to an accelerated bookbuild process, and by the draw down of c.£27.9 million of a £35.0 million extension of the Group’s debt facilities. The Placing is being conducted by means of an accelerated bookbuild process, which will be launched immediately following this announcement.

Transaction highlights
• Alliance has agreed to acquire Nizoral, a medical, anti-dandruff shampoo brand, in the APAC region from Janssen Pharmaceutica NV for a total consideration of £60 million payable to the Vendor on completion
• The consideration will be funded by a combination of the underwritten Placing to raise net proceeds of c.£32.1 million and c.£27.9 million in debt
• The Nizoral Rights include more than 15 countries including Japan, Thailand, South Korea, China and Pacific markets
• In 2017, the Nizoral Rights achieved net sales of £18.5 million1 in APAC
• Taking into account Alliance’s anticipated costs, the Nizoral Rights would have generated EBITDA on a pro forma basis in APAC (“Pro Forma EBITDA”) of £7.1 million in 2017
• The Acquisition boosts Alliance’s exposure to fast-growing APAC markets and will enhance Alliance’s APAC distributor footprint
• Nizoral will represent Alliance’s fourth International Star brand, complementing Kelo-cote™, MacuShield™ and Vamousse™
• The Acquisition is expected to generate material earnings enhancement in the first full year of ownership
1 Currency conversion rate: £1.00 = USD1.3528

Peter Butterfield, Chief Executive Officer of Alliance, commented:

“Asia-Pacific is Alliance’s fastest-growing region and we are delighted to strengthen the development of our APAC business through this earnings-enhancing acquisition of Nizoral, an excellent brand with a long medical heritage. Nizoral has significant sales, profits and growth potential in the APAC region and will become the fourth International Star brand in our product portfolio.”

For further information:

Alliance Pharma plc Tel: +44 (0) 1249 466 966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk

Numis Securities Limited Tel: +44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland
Corporate Broking: James Black

Investec Bank plc Tel: +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb / David Herring

Buchanan Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
alliancepharma@buchanan.uk.com

Latest news

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]

MVM invests in Neurolens
September 12, 2022

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]

MDxHealth acquires Oncotype DX GPS test
August 2, 2022

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO
July 14, 2022

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech
December 15, 2021

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM invests In Optinose
November 18, 2021

MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. announces pricing of Initial Public Offering
October 15, 2021

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]